This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mesfin, G. M. Articles by Wickrema Sinha, A. J. Search for Related Content PubMed PubMed Citation Articles by Mesfin, G. M. Articles by Wickrema Sinha, A. J. Social Bookmarking                         What's this?

Drug-Induced Hepatic Microgranulomatosis in Cynomolgus Monkeys

Upjohn Laboratories, 301 Henrietta Street, Kalamazoo, Michigan 49007

Michael J. Higgins

Upjohn Laboratories, 301 Henrietta Street, Kalamazoo, Michigan 49007

Bruce A. Thornburgh

Upjohn Laboratories, 301 Henrietta Street, Kalamazoo, Michigan 49007

Brian W. Jones

Upjohn Laboratories, 301 Henrietta Street, Kalamazoo, Michigan 49007

Terri L. Vande Giessen

Upjohn Laboratories, 301 Henrietta Street, Kalamazoo, Michigan 49007

Asoka J. Wickrema Sinha

Upjohn Laboratories, 301 Henrietta Street, Kalamazoo, Michigan 49007

This report discusses a unique drug-induced hepatotoxicity in cynomolgus monkeys treated orally with a novel potassium sparing experimental diuretic, [2,6-bis(4-chlorophenyl)-4-pyridinecarboxylic acid]. Groups of 6 adult male and female monkeys were treated orally with vehicle diluent, modified vehicle #122 or a suspension of the drug at 5.0, 12.5, or 32.0 mg/kg/day for 2 weeks. Another group of 5 monkeys were treated orally with 25.0 mg/kg/day of the drug for 2 weeks. Disposition of the drug was evaluated in 2 monkeys in the later group that received 27.4 mg/kg of radiolabelled drug on the 1st and last day of dosing. Hepatic toxicity was characterized biochemically, light and electron microscopically, histochemically, immunocytochemically, and toxico-kinetically. Conjugated serum bilirubin, alanine transaminase, and aspartate transaminase levels were increased in monkeys treated with over 12.5 mg/kg/day of the diuretic. The periacinar hepatic plates of monkeys treated with 25.0 or 32.0 mg/kg/day were distorted by accumulation of PAS and oil red-O positive multinucleated Kupffer cells. The cytosol of these cells was expanded by phagolysosomes containing granular materials of varying electron densities. Granular electron dense materials were also in endothelial cells and bile canaliculi. Fatty change, cholestasis, and rare piecemeal hepatic necrosis were minimal. The drug was primarily excreted through urine. Plasma concentration and half life of the drug were increased with multiple dosing. The highest concentration of unexcreted parent drug was in the liver. Drug-induced noninflammatory hepatic microgranulomatosis, apparently caused by sequestered drug-lipid/mucopolysaccharide complex in the phagocytic cells of the liver, can occur in any species, including humans, if orally administered xenobiotics are presented to the liver in particulate form.

Key Words: Liver toxicity • xenobiotic-induced hepatotoxicity • Kupffer cell granuloma • granulomatous hepatopathy • nonhuman primate

Toxicologic Pathology, Vol. 20, No. 1, 7-17 (1992)
DOI: 10.1177/019262339202000102


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. M. Walsh and C. E. Rothwell Hepatic Effects in Beagle Dogs Administered Atorvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, for 2 Years Toxicol Pathol, July 1, 1999; 27(4): 395 - 401. [Abstract] [PDF]